{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:10:44Z","timestamp":1776474644315,"version":"3.51.2"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-04449-22"],"award-info":[{"award-number":["APQ-04449-22"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-04449-22"],"award-info":[{"award-number":["APQ-04449-22"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-04449-22"],"award-info":[{"award-number":["APQ-04449-22"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00053-21"],"award-info":[{"award-number":["RED-00053-21"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["RED-00053-21"],"award-info":[{"award-number":["RED-00053-21"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2021.05027.BD"],"award-info":[{"award-number":["2021.05027.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.06611.BD"],"award-info":[{"award-number":["2020.06611.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13346-024-01772-x","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T13:40:58Z","timestamp":1735911658000},"page":"2272-2300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-5192","authenticated-orcid":false,"given":"Marina F.","family":"Dias","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-5504","authenticated-orcid":false,"given":"Estael L. C.","family":"Cruz-Cazarim","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-9512","authenticated-orcid":false,"given":"Frederico","family":"Pittella","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3314-6973","authenticated-orcid":false,"given":"Ana","family":"Bai\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-8915","authenticated-orcid":false,"given":"Ana Catarina","family":"Pacheco","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-7553","authenticated-orcid":false,"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-5211","authenticated-orcid":false,"given":"Silvia L.","family":"Fialho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"1772_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2023.07.028","volume":"361","author":"E Ramsay","year":"2023","unstructured":"Ramsay E, Lajunen T, Bhattacharya M, Reinisalo M, Rilla K, Kidron H, et al. Selective drug delivery to the retinal cells: Biological barriers and avenues. J Control Release. 2023;361:1\u201319. https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.028.","journal-title":"J Control Release"},{"key":"1772_CR2","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2024.0124","author":"F Buonfiglio","year":"2024","unstructured":"Buonfiglio F, Korb CA, Stoffelns B, Pfeiffer N, Gericke A. Recent advances in our understanding of Age-Related Macular Degeneration: mitochondrial dysfunction, Redox Signaling, and the complement system. Aging Dis. 2024. https:\/\/doi.org\/10.14336\/AD.2024.0124.","journal-title":"Aging Dis"},{"key":"1772_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"EM Del Amo","year":"2017","unstructured":"Del Amo EM, Rimpela AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134\u201385. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.12.001.","journal-title":"Prog Retin Eye Res"},{"key":"1772_CR4","doi-asserted-by":"publisher","first-page":"114770","DOI":"10.1016\/j.addr.2023.114770","volume":"196","author":"H Han","year":"2023","unstructured":"Han H, Li S, Xu M, Zhong Y, Fan W, Xu J, et al. Polymer- and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives. Adv Drug Deliv Rev. 2023;196:114770. https:\/\/doi.org\/10.1016\/j.addr.2023.114770.","journal-title":"Adv Drug Deliv Rev"},{"key":"1772_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jconrel.2022.08.026","volume":"350","author":"B Xue","year":"2022","unstructured":"Xue B, Ge M, Fan K, Huang X, Yan X, Jiang W, et al. Mitochondria-targeted nanozymes eliminate oxidative damage in retinal neovascularization disease. J Control Release. 2022;350:271\u201383. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.026.","journal-title":"J Control Release"},{"key":"1772_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fphar.2020.00234","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T, Tsirukis DI, Sun Y. Targeting neuroinflammation in Neovascular Retinal diseases. Front Pharmacol. 2020;11:234. https:\/\/doi.org\/10.3389\/fphar.2020.00234.","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"1772_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.survophthal.2006.10.017","volume":"52","author":"M Dorrell","year":"2007","unstructured":"Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol. 2007;52(Suppl 1):S3\u201319. https:\/\/doi.org\/10.1016\/j.survophthal.2006.10.017.","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"1772_CR8","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3390\/cells10081957","volume":"10","author":"A Salman","year":"2021","unstructured":"Salman A, McClements ME, MacLaren RE. Insights on the Regeneration Potential of Muller Glia in the Mammalian Retina. Cells. 2021;10(8): 1957. https:\/\/doi.org\/10.3390\/cells10081957.","journal-title":"Cells"},{"issue":"7","key":"1772_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrn3723","volume":"15","author":"D Goldman","year":"2014","unstructured":"Goldman D. Muller glial cell reprogramming and retina regeneration. Nat Rev Neurosci. 2014;15(7):431\u201342. https:\/\/doi.org\/10.1038\/nrn3723.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1772_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1167\/iovs.65.2.42","volume":"65","author":"S Navneet","year":"2024","unstructured":"Navneet S, Wilson K, Rohrer B. Muller glial cells in the Macula: their activation and cell-cell interactions in age-related Macular Degeneration. Invest Ophthalmol Vis Sci. 2024;65(2):42. https:\/\/doi.org\/10.1167\/iovs.65.2.42.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1772_CR11","doi-asserted-by":"crossref","unstructured":"Nag TC. M\u00fcller cell vulnerability in aging human retina: Implications on photoreceptor cell survival. 2023.","DOI":"10.1016\/j.exer.2023.109645"},{"key":"1772_CR12","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.preteyeres.2019.07.005","volume":"74","author":"M Power","year":"2020","unstructured":"Power M, Das S, Schutze K, Marigo V, Ekstrom P, Paquet-Durand F. Cellular mechanisms of hereditary photoreceptor degeneration - focus on cGMP. Prog Retin Eye Res. 2020;74:100772. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.005.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1772_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/antiox8010003","volume":"8","author":"VE Baksheeva","year":"2018","unstructured":"Baksheeva VE, Tiulina VV, Tikhomirova NK, Gancharova OS, Komarov SV, Philippov PP, et al. Suppression of Light-Induced oxidative stress in the Retina by Mitochondria-Targeted Antioxidant. Antioxid (Basel). 2018;8(1): 3. https:\/\/doi.org\/10.3390\/antiox8010003.","journal-title":"Antioxid (Basel)"},{"issue":"22","key":"1772_CR14","doi-asserted-by":"publisher","first-page":"22800","DOI":"10.1021\/acsnano.3c07517","volume":"17","author":"S Cupini","year":"2023","unstructured":"Cupini S, Di Marco S, Boselli L, Cavalli A, Tarricone G, Mastronardi V, et al. Platinum nanozymes counteract photoreceptor degeneration and Retina Inflammation in a light-damage model of age-related Macular Degeneration. ACS Nano. 2023;17(22):22800\u201320. https:\/\/doi.org\/10.1021\/acsnano.3c07517.","journal-title":"ACS Nano"},{"issue":"8","key":"1772_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/antiox9080761","volume":"9","author":"Y Ruan","year":"2020","unstructured":"Ruan Y, Jiang S, Musayeva A, Gericke A. Oxidative stress and vascular dysfunction in the retina: therapeutic strategies. Antioxid (Basel). 2020;9(8): 761. https:\/\/doi.org\/10.3390\/antiox9080761.","journal-title":"Antioxid (Basel)"},{"issue":"4","key":"1772_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/antiox13040394","volume":"13","author":"J Yang","year":"2024","unstructured":"Yang J, Luo J, Tian X, Zhao Y, Li Y, Wu X. Progress in understanding oxidative stress, aging, and aging-related diseases. Antioxid (Basel). 2024;13(4): 394. https:\/\/doi.org\/10.3390\/antiox13040394.","journal-title":"Antioxid (Basel)"},{"issue":"2","key":"1772_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/eye.2015.221","volume":"30","author":"MA Contin","year":"2016","unstructured":"Contin MA, Benedetto MM, Quinteros-Quintana ML, Guido ME. Light pollution: the possible consequences of excessive illumination on retina. Eye (Lond). 2016;30(2):255\u201363. https:\/\/doi.org\/10.1038\/eye.2015.221.","journal-title":"Eye (Lond)"},{"key":"1772_CR18","doi-asserted-by":"publisher","first-page":"109942","DOI":"10.1016\/j.envres.2020.109942","volume":"190","author":"Y Touitou","year":"2020","unstructured":"Touitou Y, Point S. Effects and mechanisms of action of light-emitting diodes on the human retina and internal clock. Environ Res. 2020;190:109942. https:\/\/doi.org\/10.1016\/j.envres.2020.109942.","journal-title":"Environ Res"},{"issue":"23","key":"1772_CR19","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.3390\/jcm10235496","volume":"10","author":"A Shinojima","year":"2021","unstructured":"Shinojima A, Lee D, Tsubota K, Negishi K, Kurihara T. Retinal diseases regulated by Hypoxia-Basic and Clinical perspectives: a Comprehensive Review. J Clin Med. 2021;10(23):5496. https:\/\/doi.org\/10.3390\/jcm10235496.","journal-title":"J Clin Med"},{"issue":"6","key":"1772_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/10915810290169927","volume":"21","author":"DH Sliney","year":"2002","unstructured":"Sliney DH. How light reaches the eye and its components. Int J Toxicol. 2002;21(6):501\u20139. https:\/\/doi.org\/10.1080\/10915810290169927.","journal-title":"Int J Toxicol"},{"issue":"8\u20139","key":"1772_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1051\/medsci\/2020133","volume":"36","author":"A Torriglia","year":"2020","unstructured":"Torriglia A, Mascarelli F, Behar-Cohen F. [New lighting technology and our eyes]. Med Sci (Paris). 2020;36(8\u20139):769\u201373. https:\/\/doi.org\/10.1051\/medsci\/2020133.","journal-title":"Med Sci (Paris)"},{"issue":"3","key":"1772_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1515\/revneuro-2023-0130","volume":"35","author":"G Carozza","year":"2024","unstructured":"Carozza G, Zerti D, Tisi A, Ciancaglini M, Maccarrone M, Maccarone R. An overview of retinal light damage models for preclinical studies on age-related macular degeneration: identifying molecular hallmarks and therapeutic targets. Rev Neurosci. 2024;35(3):303\u201330. https:\/\/doi.org\/10.1515\/revneuro-2023-0130.","journal-title":"Rev Neurosci"},{"issue":"6","key":"1772_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/10915810290169909","volume":"21","author":"RD Glickman","year":"2002","unstructured":"Glickman RD. Phototoxicity to the retina: mechanisms of damage. Int J Toxicol. 2002;21(6):473\u201390. https:\/\/doi.org\/10.1080\/10915810290169909.","journal-title":"Int J Toxicol"},{"issue":"12","key":"1772_CR24","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.3390\/antiox12122072","volume":"12","author":"A Fietz","year":"2023","unstructured":"Fietz A, Corsi F, Hurst J, Schnichels S. Blue light damage and p53: unravelling the role of p53 in oxidative-stress-Induced Retinal apoptosis. Antioxid (Basel). 2023;12(12):2072. https:\/\/doi.org\/10.3390\/antiox12122072.","journal-title":"Antioxid (Basel)"},{"key":"1772_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fncel.2019.00139","volume":"13","author":"MM Benedetto","year":"2019","unstructured":"Benedetto MM, Contin MA. Oxidative stress in Retinal Degeneration promoted by constant LED light. Front Cell Neurosci. 2019;13:139. https:\/\/doi.org\/10.3389\/fncel.2019.00139.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"1772_CR26","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.1038\/s41598-020-63449-y","volume":"10","author":"A Tisi","year":"2020","unstructured":"Tisi A, Parete G, Flati V, Maccarone R. Up-regulation of pro-angiogenic pathways and induction of neovascularization by an acute retinal light damage. Sci Rep. 2020;10(1):6376. https:\/\/doi.org\/10.1038\/s41598-020-63449-y.","journal-title":"Sci Rep"},{"issue":"10","key":"1772_CR27","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.4103\/1673-5374.369098","volume":"18","author":"M Maurya","year":"2023","unstructured":"Maurya M, Bora K, Blomfield AK, Pavlovich MC, Huang S, Liu CH, et al. Oxidative stress in retinal pigment epithelium degeneration: from pathogenesis to therapeutic targets in dry age-related macular degeneration. Neural Regen Res. 2023;18(10):2173\u201381. https:\/\/doi.org\/10.4103\/1673-5374.369098.","journal-title":"Neural Regen Res"},{"issue":"8","key":"1772_CR28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/ceo.14294","volume":"51","author":"S Girgis","year":"2023","unstructured":"Girgis S, Lee LR. Treatment of dry age-related macular degeneration: a review. Clin Exp Ophthalmol. 2023;51(8):835\u201352. https:\/\/doi.org\/10.1111\/ceo.14294.","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"1772_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.survophthal.2023.11.003","volume":"69","author":"S Jabbehdari","year":"2024","unstructured":"Jabbehdari S, Oganov AC, Rezagholi F, Mohammadi S, Harandi H, Yazdanpanah G, et al. Age-related macular degeneration and neurodegenerative disorders: Shared pathways in complex interactions. Surv Ophthalmol. 2024;69(3):303\u201310. https:\/\/doi.org\/10.1016\/j.survophthal.2023.11.003.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"1772_CR30","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9(4):e489\u2013551. https:\/\/doi.org\/10.1016\/S2214-109X(20)30488-5.","journal-title":"Lancet Glob Health"},{"issue":"10386","key":"1772_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023;401(10386):1459\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(22)02609-5.","journal-title":"Lancet"},{"issue":"2","key":"1772_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/life13020568","volume":"13","author":"H Paliwal","year":"2023","unstructured":"Paliwal H, Prajapati BG, Srichana T, Singh S, Patel RJ. Novel approaches in the Drug Development and Delivery systems for Age-Related Macular Degeneration. Life (Basel). 2023;13(2):568. https:\/\/doi.org\/10.3390\/life13020568.","journal-title":"Life (Basel)"},{"issue":"4","key":"1772_CR33","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.3390\/ijms25042386","volume":"25","author":"J Blasiak","year":"2024","unstructured":"Blasiak J, Pawlowska E, Ciupinska J, Derwich M, Szczepanska J, Kaarniranta K. A New Generation of Gene therapies as the future of Wet AMD Treatment. Int J Mol Sci. 2024;25(4):2386. https:\/\/doi.org\/10.3390\/ijms25042386.","journal-title":"Int J Mol Sci"},{"key":"1772_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.actbio.2023.09.025","volume":"171","author":"S Lee","year":"2023","unstructured":"Lee S, Hong HK, Song JS, Jeong SI, Chung JY, Woo SJ, et al. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina. Acta Biomater. 2023;171:273\u201388. https:\/\/doi.org\/10.1016\/j.actbio.2023.09.025.","journal-title":"Acta Biomater"},{"key":"1772_CR35","doi-asserted-by":"publisher","first-page":"113708","DOI":"10.1016\/j.colsurfb.2023.113708","volume":"234","author":"M Malakouti-Nejad","year":"2024","unstructured":"Malakouti-Nejad M, Monti D, Burgalassi S, Bardania H, Elahi E, Morshedi D. A comparison between the effects of two liposome-encapsulated bevacizumab formulations on ocular neovascularization inhibition. Colloids Surf B Biointerfaces. 2024;234:113708. https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113708.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1772_CR36","doi-asserted-by":"publisher","first-page":"251584142110726","DOI":"10.1177\/25158414211072623","volume":"14","author":"PR Chandrasekaran","year":"2022","unstructured":"Chandrasekaran PR, Madanagopalan VG. Ranibizumab port delivery system in neovascular age-related macular degeneration. Ther Adv Ophthalmol. 2022;14:25158414211072623. https:\/\/doi.org\/10.1177\/25158414211072623.","journal-title":"Ther Adv Ophthalmol"},{"key":"1772_CR37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jconrel.2022.10.036","volume":"352","author":"JH Jung","year":"2022","unstructured":"Jung JH, Kim SS, Chung H, Hejri A, Prausnitz MR. Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space. J Control Release. 2022;352:472\u201384. https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.036.","journal-title":"J Control Release"},{"issue":"4","key":"1772_CR38","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/pharmaceutics15041264","volume":"15","author":"S Yaylaci","year":"2023","unstructured":"Yaylaci S, Dinc E, Aydin B, Tekinay AB, Guler MO. Peptide Nanofiber System for sustained delivery of Anti-VEGF proteins to the Eye Vitreous. Pharmaceutics. 2023;15(4):1264. https:\/\/doi.org\/10.3390\/pharmaceutics15041264.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1772_CR39","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.omtm.2024.101242","volume":"32","author":"SH Haldrup","year":"2024","unstructured":"Haldrup SH, Fabian-Jessing BK, Jakobsen TS, Lindholm AB, Adsersen RL, Aagaard L, et al. Subretinal AAV delivery of RNAi-therapeutics targeting VEGFA reduces choroidal neovascularization in a large animal model. Mol Ther Methods Clin Dev. 2024;32(2):101242. https:\/\/doi.org\/10.1016\/j.omtm.2024.101242.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"1772_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/acs.molpharmaceut.0c00992","volume":"18","author":"X Huang","year":"2021","unstructured":"Huang X, Chau Y. Enhanced delivery of siRNA to retinal ganglion cells by Intravitreal lipid nanoparticles of positive charge. Mol Pharm. 2021;18(1):377\u201385. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00992.","journal-title":"Mol Pharm"},{"issue":"1","key":"1772_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5114\/ceji.2022.113103","volume":"47","author":"K Samelska","year":"2022","unstructured":"Samelska K, Kupis M, Izdebska J, Kaminska A, Skopinski P. Novel approach to antiangiogenic factors in age-related macular degeneration therapy. Cent Eur J Immunol. 2022;47(1):117\u201323. https:\/\/doi.org\/10.5114\/ceji.2022.113103.","journal-title":"Cent Eur J Immunol"},{"issue":"1","key":"1772_CR42","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1038\/s41598-023-29014-z","volume":"13","author":"J Park","year":"2023","unstructured":"Park J, Cui G, Lee H, Jeong H, Kwak JJ, Lee J, et al. CRISPR\/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization. Sci Rep. 2023;13(1):3715. https:\/\/doi.org\/10.1038\/s41598-023-29014-z.","journal-title":"Sci Rep"},{"issue":"1","key":"1772_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ymthe.2020.09.032","volume":"29","author":"AB Holmgaard","year":"2021","unstructured":"Holmgaard AB, Askou AL, Jensen EG, Alsing S, Bak RO, Mikkelsen JG, et al. Targeted knockout of the Vegfa Gene in the Retina by Subretinal Injection of RNP complexes containing Cas9 protein and modified sgRNAs. Mol Ther. 2021;29(1):191\u2013207. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.032.","journal-title":"Mol Ther"},{"issue":"10436","key":"1772_CR44","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, Avery R, Brown DM, Heier JS, Ho AC, Huddleston SM, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. Lancet. 2024;403(10436):1563\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(24)00310-6.","journal-title":"Lancet"},{"key":"1772_CR45","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jconrel.2023.01.080","volume":"355","author":"W Li","year":"2023","unstructured":"Li W, Chen L, Gu Z, Chen Z, Li H, Cheng Z, et al. Co-delivery of microRNA-150 and quercetin by lipid nanoparticles (LNPs) for the targeted treatment of age-related macular degeneration (AMD). J Control Release. 2023;355:358\u201370. https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.080.","journal-title":"J Control Release"},{"issue":"13","key":"1772_CR46","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.1167\/iovs.18-24926","volume":"59","author":"SHS Lee","year":"2018","unstructured":"Lee SHS, Kim HJ, Shin OK, Choi JS, Kim J, Cho YH, et al. Intravitreal Injection of AAV expressing Soluble VEGF Receptor-1 variant induces Anti-VEGF activity and suppresses Choroidal Neovascularization. Invest Ophthalmol Vis Sci. 2018;59(13):5398\u2013407. https:\/\/doi.org\/10.1167\/iovs.18-24926.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10411","key":"1772_CR47","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","volume":"402","author":"JS Heier","year":"2023","unstructured":"Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402(10411):1434\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(23)01520-9.","journal-title":"Lancet"},{"issue":"10411","key":"1772_CR48","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402(10411):1449\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(23)01583-0.","journal-title":"Lancet"},{"key":"1772_CR49","doi-asserted-by":"publisher","first-page":"9945725","DOI":"10.1155\/2021\/9945725","volume":"2021","author":"S Qin","year":"2021","unstructured":"Qin S, Dong N, Yang M, Wang J, Feng X, Wang Y. Complement inhibitors in age-related Macular Degeneration: a potential therapeutic option. J Immunol Res. 2021;2021:9945725. https:\/\/doi.org\/10.1155\/2021\/9945725.","journal-title":"J Immunol Res"},{"issue":"2","key":"1772_CR50","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1167\/iovs.16-21272","volume":"58","author":"MR Biswal","year":"2017","unstructured":"Biswal MR, Han P, Zhu P, Wang Z, Li H, Ildefonso CJ, et al. Timing of antioxidant gene therapy: implications for treating Dry AMD. Invest Ophthalmol Vis Sci. 2017;58(2):1237\u201345. https:\/\/doi.org\/10.1167\/iovs.16-21272.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"1772_CR51","doi-asserted-by":"publisher","first-page":"CD000254","DOI":"10.1002\/14651858.CD000254.pub5","volume":"9","author":"JR Evans","year":"2023","unstructured":"Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023;9(9):CD000254. https:\/\/doi.org\/10.1002\/14651858.CD000254.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"1772_CR52","doi-asserted-by":"publisher","first-page":"109862","DOI":"10.1016\/j.exer.2024.109862","volume":"242","author":"S Gu","year":"2024","unstructured":"Gu S, Wu S, Lin Z, Han Z, Mo K, Huang H, et al. Screening and evaluation of antioxidants for retinal pigment epithelial cell protection: L-ergothioneine as a novel therapeutic candidate through NRF2 activation. Exp Eye Res. 2024;242:109862. https:\/\/doi.org\/10.1016\/j.exer.2024.109862.","journal-title":"Exp Eye Res"},{"key":"1772_CR53","doi-asserted-by":"publisher","first-page":"114259","DOI":"10.1016\/j.biopha.2023.114259","volume":"159","author":"M Sun","year":"2023","unstructured":"Sun M, Yu T, Zhao J, Zhu X, Xin W, Zhang F, et al. Role of flavonoids in age-related macular degeneration. Biomed Pharmacother. 2023;159:114259. https:\/\/doi.org\/10.1016\/j.biopha.2023.114259.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1772_CR54","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.3390\/ijms24065296","volume":"24","author":"V Fontaine","year":"2023","unstructured":"Fontaine V, Balducci C, Dinan L, Monteiro E, Boumedine T, Fournie M, et al. Anti-Inflammatory Effects and Photo- and Neuro-Protective Properties of BIO203, a New Amide Conjugate of Norbixin, in Development for the Treatment of Age-Related Macular Degeneration (AMD). Int J Mol Sci. 2023;24(6):5296. https:\/\/doi.org\/10.3390\/ijms24065296.","journal-title":"Int J Mol Sci"},{"key":"1772_CR55","doi-asserted-by":"publisher","first-page":"109879","DOI":"10.1016\/j.exer.2024.109879","volume":"242","author":"TT Lee","year":"2024","unstructured":"Lee TT, Bell BA, Anderson BD, Song Y, Dunaief JL. Tamoxifen protects photoreceptors in the sodium iodate model. Exp Eye Res. 2024;242:109879. https:\/\/doi.org\/10.1016\/j.exer.2024.109879.","journal-title":"Exp Eye Res"},{"issue":"3","key":"1772_CR56","doi-asserted-by":"publisher","first-page":"e0300045","DOI":"10.1371\/journal.pone.0300045","volume":"19","author":"Y Miwa","year":"2024","unstructured":"Miwa Y, Lee D, Shoda C, Jeong H, Negishi K, Kurihara T. Halofuginone prevents outer retinal degeneration in a mouse model of light-induced retinopathy. PLoS ONE. 2024;19(3):e0300045. https:\/\/doi.org\/10.1371\/journal.pone.0300045.","journal-title":"PLoS ONE"},{"key":"1772_CR57","doi-asserted-by":"publisher","first-page":"108765","DOI":"10.1016\/j.exer.2021.108765","volume":"212","author":"T Racic","year":"2021","unstructured":"Racic T, Chang A, Fernando N, Brandli A, Natoli R, Penfold P, et al. Anti-inflammatory and neuroprotective properties of the corticosteroid fludrocortisone in retinal degeneration. Exp Eye Res. 2021;212:108765. https:\/\/doi.org\/10.1016\/j.exer.2021.108765.","journal-title":"Exp Eye Res"},{"key":"1772_CR58","doi-asserted-by":"publisher","first-page":"102113","DOI":"10.1016\/j.npep.2020.102113","volume":"85","author":"LFN Dourado","year":"2021","unstructured":"Dourado LFN, Silva CN, Dos Anjos LC, Mortari MR, Silva-Cunha A, Fialho SL. Ischemia-induced retinal injury is attenuated by Neurovespina, a peptide from the venom of the social wasp Polybia Occidentalis. Neuropeptides. 2021;85:102113. https:\/\/doi.org\/10.1016\/j.npep.2020.102113.","journal-title":"Neuropeptides"},{"issue":"10","key":"1772_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/iovs.64.10.25","volume":"64","author":"D Grigsby","year":"2023","unstructured":"Grigsby D, Klingeborn M, Kelly U, Chew LA, Asokan A, Devlin G, et al. AAV Gene Augmentation of Truncated Complement Factor H Differentially rescues ocular complement dysregulation in a mouse model. Invest Ophthalmol Vis Sci. 2023;64(10):25. https:\/\/doi.org\/10.1167\/iovs.64.10.25.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1772_CR60","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.ymthe.2023.03.029","volume":"31","author":"X Qi","year":"2023","unstructured":"Qi X, Francelin C, Mitter S, Boye SL, Gu H, Quigley J, et al. beta-secretase 1 overexpression by AAV-mediated gene delivery prevents retina degeneration in a mouse model of age-related macular degeneration. Mol Ther. 2023;31(7):2042\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.029.","journal-title":"Mol Ther"},{"issue":"5\u20136","key":"1772_CR61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/hum.2023.201","volume":"35","author":"X Sun","year":"2024","unstructured":"Sun X, Liang C, Chen Y, Cui T, Han J, Dai M, et al. Knockout and replacement gene surgery to treat rhodopsin-mediated autosomal Dominant Retinitis Pigmentosa. Hum Gene Ther. 2024;35(5\u20136):151\u201362. https:\/\/doi.org\/10.1089\/hum.2023.201.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"1772_CR62","doi-asserted-by":"publisher","first-page":"e13635","DOI":"10.1111\/cpr.13635","volume":"57","author":"Q Wu","year":"2024","unstructured":"Wu Q, Zhu J, Zhang X, Xu X, Luo D, Lin Y, et al. The antioxidant effect of tetrahedral framework nucleic acid-based delivery of small activating RNA targeting DJ-1 on retinal oxidative stress injury. Cell Prolif. 2024;57(8):e13635. https:\/\/doi.org\/10.1111\/cpr.13635.","journal-title":"Cell Prolif"},{"issue":"2","key":"1772_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1167\/iovs.61.2.45","volume":"61","author":"SHS Lee","year":"2020","unstructured":"Lee SHS, Chang H, Kim JH, Kim HJ, Choi JS, Chung S, et al. Inhibition of mTOR via an AAV-Delivered shRNA tested in a rat OIR model as a potential antiangiogenic gene therapy. Invest Ophthalmol Vis Sci. 2020;61(2):45. https:\/\/doi.org\/10.1167\/iovs.61.2.45.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1772_CR64","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.stem.2023.11.004","volume":"30","author":"Y Hirami","year":"2023","unstructured":"Hirami Y, Mandai M, Sugita S, Maeda A, Maeda T, Yamamoto M, et al. Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa. Cell Stem Cell. 2023;30(12):1585\u2013e966. https:\/\/doi.org\/10.1016\/j.stem.2023.11.004.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"1772_CR65","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2023.12.028","volume":"131","author":"MS Humayun","year":"2024","unstructured":"Humayun MS, Clegg DO, Dayan MS, Kashani AH, Rahhal FM, Avery RL, et al. Long-term follow-up of a phase 1\/2a clinical trial of a stem cell-derived Bioengineered Retinal Pigment Epithelium Implant for Geographic Atrophy. Ophthalmology. 2024;131(6):682\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.028.","journal-title":"Ophthalmology"},{"issue":"1","key":"1772_CR66","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1186\/s12967-023-04785-1","volume":"21","author":"Q Liu","year":"2023","unstructured":"Liu Q, Liu J, Guo M, Sung TC, Wang T, Yu T, et al. Comparison of retinal degeneration treatment with four types of different mesenchymal stem cells, human induced pluripotent stem cells and RPE cells in a rat retinal degeneration model. J Transl Med. 2023;21(1):910. https:\/\/doi.org\/10.1186\/s12967-023-04785-1.","journal-title":"J Transl Med"},{"key":"1772_CR67","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jconrel.2023.04.003","volume":"357","author":"Y Tang","year":"2023","unstructured":"Tang Y, Kang Y, Zhang X, Cheng C. Mesenchymal stem cell exosomes as nanotherapeutics for dry age-related macular degeneration. J Control Release. 2023;357:356\u201370. https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.003.","journal-title":"J Control Release"},{"issue":"9","key":"1772_CR68","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.3390\/antiox11091790","volume":"11","author":"M Nebbioso","year":"2022","unstructured":"Nebbioso M, Franzone F, Lambiase A, Bonfiglio V, Limoli PG, Artico M, et al. Oxidative stress implication in retinal Diseases-A Review. Antioxid (Basel). 2022;11(9):1790. https:\/\/doi.org\/10.3390\/antiox11091790.","journal-title":"Antioxid (Basel)"},{"key":"1772_CR69","doi-asserted-by":"publisher","first-page":"108255","DOI":"10.1016\/j.exer.2020.108255","volume":"201","author":"TC Chan","year":"2020","unstructured":"Chan TC, Wilkinson Berka JL, Deliyanti D, Hunter D, Fung A, Liew G, et al. The role of reactive oxygen species in the pathogenesis and treatment of retinal diseases. Exp Eye Res. 2020;201:108255. https:\/\/doi.org\/10.1016\/j.exer.2020.108255.","journal-title":"Exp Eye Res"},{"issue":"4","key":"1772_CR70","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/antiox9040347","volume":"9","author":"EBD Marfany","year":"2020","unstructured":"Marfany EBD. The relevance of oxidative stress in the Pathogenesis and therapy of Retinal dystrophies. Antioxid (Basel). 2020;9(4):347. https:\/\/doi.org\/10.3390\/antiox9040347.","journal-title":"Antioxid (Basel)"},{"issue":"3","key":"1772_CR71","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/antiox13030362","volume":"13","author":"R Salceda","year":"2024","unstructured":"Salceda R. Light Pollution and oxidative stress: effects on retina and Human Health. Antioxid (Basel). 2024;13(3):362. https:\/\/doi.org\/10.3390\/antiox13030362.","journal-title":"Antioxid (Basel)"},{"key":"1772_CR72","doi-asserted-by":"publisher","first-page":"102967","DOI":"10.1016\/j.redox.2023.102967","volume":"68","author":"EW Bohm","year":"2023","unstructured":"Bohm EW, Buonfiglio F, Voigt AM, Bachmann P, Safi T, Pfeiffer N, et al. Oxidative stress in the eye and its role in the pathophysiology of ocular diseases. Redox Biol. 2023;68:102967. https:\/\/doi.org\/10.1016\/j.redox.2023.102967.","journal-title":"Redox Biol"},{"key":"1772_CR73","doi-asserted-by":"publisher","first-page":"102862","DOI":"10.1016\/j.redox.2023.102862","volume":"66","author":"R Garcia-Arroyo","year":"2023","unstructured":"Garcia-Arroyo R, Domenech EB, Herrera-Ubeda C, Asensi MA, Nunez de Arenas C, Cuezva JM, et al. Exacerbated response to oxidative stress in the Retinitis Pigmentosa Cerkl(KD\/KO) mouse model triggers retinal degeneration pathways upon acute light stress. Redox Biol. 2023;66:102862. https:\/\/doi.org\/10.1016\/j.redox.2023.102862.","journal-title":"Redox Biol"},{"issue":"15","key":"1772_CR74","doi-asserted-by":"publisher","first-page":"12090","DOI":"10.3390\/ijms241512090","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang X, Wang T, Lam E, Alvarez D, Sun Y. Ocular vascular diseases: from Retinal Immune privilege to inflammation. Int J Mol Sci. 2023;24(15):12090. https:\/\/doi.org\/10.3390\/ijms241512090.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1772_CR75","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.14336\/AD.2023.0823-3","volume":"15","author":"N Zhao","year":"2024","unstructured":"Zhao N, Hao XN, Huang JM, Song ZM, Tao Y. Crosstalk between Microglia and Muller Glia in the age-related Macular Degeneration: role and therapeutic value of Neuroinflammation. Aging Dis. 2024;15(3):1132\u201354. https:\/\/doi.org\/10.14336\/AD.2023.0823-3.","journal-title":"Aging Dis"},{"key":"1772_CR76","doi-asserted-by":"publisher","first-page":"594984","DOI":"10.3389\/fgeed.2020.594984","volume":"2","author":"SH Chung","year":"2020","unstructured":"Chung SH, Sin TN, Ngo T, Yiu G. CRISPR Technology for Ocular Angiogenesis. Front Genome Ed. 2020;2:594984. https:\/\/doi.org\/10.3389\/fgeed.2020.594984.","journal-title":"Front Genome Ed"},{"key":"1772_CR77","doi-asserted-by":"publisher","first-page":"115535","DOI":"10.1016\/j.ejmech.2023.115535","volume":"257","author":"D Jiang","year":"2023","unstructured":"Jiang D, Xu T, Zhong L, Liang Q, Hu Y, Xiao W, et al. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. Eur J Med Chem. 2023;257:115535. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115535.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"1772_CR78","doi-asserted-by":"publisher","first-page":"e22307","DOI":"10.1016\/j.heliyon.2023.e22307","volume":"9","author":"R Zhang","year":"2023","unstructured":"Zhang R, Wang L, Li Y, Gui C, Pei Y, Zhou G. Roles and mechanisms of long non-coding RNAs in age-related macular degeneration. Heliyon. 2023;9(11):e22307. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22307.","journal-title":"Heliyon"},{"key":"1772_CR79","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.exer.2020.108329","volume":"202","author":"S Supe","year":"2021","unstructured":"Supe S, Upadhya A, Singh K. Role of small interfering RNA (siRNA) in targeting ocular neovascularization: a review. Exp Eye Res. 2021;202:108329. https:\/\/doi.org\/10.1016\/j.exer.2020.108329.","journal-title":"Exp Eye Res"},{"key":"1772_CR80","doi-asserted-by":"publisher","first-page":"106946","DOI":"10.1016\/j.phrs.2023.106946","volume":"197","author":"W Zhang","year":"2023","unstructured":"Zhang W, He Y, Zhang Y. CircRNA in ocular neovascular diseases: fundamental mechanism and clinical potential. Pharmacol Res. 2023;197:106946. https:\/\/doi.org\/10.1016\/j.phrs.2023.106946.","journal-title":"Pharmacol Res"},{"issue":"15","key":"1772_CR81","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.21037\/atm-20-4417","volume":"9","author":"SH Chung","year":"2021","unstructured":"Chung SH, Frick SL, Yiu G. Targeting vascular endothelial growth factor using retinal gene therapy. Ann Transl Med. 2021;9(15):1277. https:\/\/doi.org\/10.21037\/atm-20-4417.","journal-title":"Ann Transl Med"},{"key":"1772_CR82","doi-asserted-by":"publisher","first-page":"738325","DOI":"10.3389\/fcvm.2021.738325","volume":"8","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhu X, Cui H, Shi J, Yuan G, Shi S, et al. The role of the VEGF family in Coronary Heart Disease. Front Cardiovasc Med. 2021;8:738325. https:\/\/doi.org\/10.3389\/fcvm.2021.738325.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1772_CR83","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3390\/ijms23020931","volume":"23","author":"SA Dabravolski","year":"2022","unstructured":"Dabravolski SA, Khotina VA, Omelchenko AV, Kalmykov VA, Orekhov AN. The role of the VEGF family in Atherosclerosis Development and its potential as treatment targets. Int J Mol Sci. 2022;23(2):931. https:\/\/doi.org\/10.3390\/ijms23020931.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1772_CR84","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1590\/s0004-27492006000500027","volume":"69","author":"EB Rodrigues","year":"2006","unstructured":"Rodrigues EB, Rossi EE, Grumann Junior A, Meyer CH, Ho AC. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. Arq Bras Oftalmol. 2006;69(5):756\u201365. https:\/\/doi.org\/10.1590\/s0004-27492006000500027.","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"1772_CR85","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331\u201371. https:\/\/doi.org\/10.1016\/j.preteyeres.2008.05.001.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"1772_CR86","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s12276-021-00566-2","volume":"53","author":"A Mukwaya","year":"2021","unstructured":"Mukwaya A, Jensen L, Lagali N. Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies. Exp Mol Med. 2021;53(2):189\u2013201. https:\/\/doi.org\/10.1038\/s12276-021-00566-2.","journal-title":"Exp Mol Med"},{"issue":"6801","key":"1772_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249\u201357. https:\/\/doi.org\/10.1038\/35025220.","journal-title":"Nature"},{"issue":"4","key":"1772_CR88","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/ijms19041264","volume":"19","author":"CJ Peach","year":"2018","unstructured":"Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. Int J Mol Sci. 2018;19(4):1264. https:\/\/doi.org\/10.3390\/ijms19041264.","journal-title":"Int J Mol Sci"},{"key":"1772_CR89","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","volume":"103","author":"M Amadio","year":"2016","unstructured":"Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: what\u2019s new? A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res. 2016;103:253\u201369. https:\/\/doi.org\/10.1016\/j.phrs.2015.11.027.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1772_CR90","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1590\/s0004-27492007000300030","volume":"70","author":"FM Damico","year":"2007","unstructured":"Damico FM. [Angiogenesis and retinal diseases]. Arq Bras Oftalmol. 2007;70(3):547\u201353. https:\/\/doi.org\/10.1590\/s0004-27492007000300030.","journal-title":"Arq Bras Oftalmol"},{"issue":"6","key":"1772_CR91","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4161\/cam.22439","volume":"6","author":"M Peiris-Pages","year":"2012","unstructured":"Peiris-Pages M. The role of VEGF 165b in pathophysiology. Cell Adh Migr. 2012;6(6):561\u20138. https:\/\/doi.org\/10.4161\/cam.22439.","journal-title":"Cell Adh Migr"},{"issue":"11","key":"1772_CR92","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s00125-005-1951-8","volume":"48","author":"RM Perrin","year":"2005","unstructured":"Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48(11):2422\u20137. https:\/\/doi.org\/10.1007\/s00125-005-1951-8.","journal-title":"Diabetologia"},{"issue":"2","key":"1772_CR93","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/08820538.2022.2152706","volume":"38","author":"S Vishwakarma","year":"2023","unstructured":"Vishwakarma S, Kaur I. Molecular mediators and regulators of Retinal Angiogenesis. Semin Ophthalmol. 2023;38(2):124\u201333. https:\/\/doi.org\/10.1080\/08820538.2022.2152706.","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"1772_CR94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13578-024-01205-9","volume":"14","author":"P Liu","year":"2024","unstructured":"Liu P, Sun D, Zhang S, Chen S, Wang X, Li H, et al. PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies. Cell Biosci. 2024;14(1):21. https:\/\/doi.org\/10.1186\/s13578-024-01205-9.","journal-title":"Cell Biosci"},{"issue":"5","key":"1772_CR95","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.3390\/ijms23052592","volume":"23","author":"AR Fernandes","year":"2022","unstructured":"Fernandes AR, Zielinska A, Sanchez-Lopez E, Dos Santos T, Garcia ML, Silva AM, et al. Exudative versus nonexudative age-related Macular Degeneration: Physiopathology and Treatment options. Int J Mol Sci. 2022;23(5):2592. https:\/\/doi.org\/10.3390\/ijms23052592.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1772_CR96","doi-asserted-by":"publisher","first-page":"e2304626","DOI":"10.1002\/adhm.202304626","volume":"13","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Xu M, Shen W, Xu Y, Shao A, Xu P, et al. Recent advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management. Adv Healthc Mater. 2024;13(17):e2304626. https:\/\/doi.org\/10.1002\/adhm.202304626.","journal-title":"Adv Healthc Mater"},{"issue":"5","key":"1772_CR97","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/pharmaceutics14050998","volume":"14","author":"B Leclercq","year":"2022","unstructured":"Leclercq B, Mejlachowicz D, Behar-Cohen F. Ocular barriers and their influence on Gene Therapy products Delivery. Pharmaceutics. 2022;14(5):998. https:\/\/doi.org\/10.3390\/pharmaceutics14050998.","journal-title":"Pharmaceutics"},{"issue":"7","key":"1772_CR98","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/1061186X.2021.1878366","volume":"29","author":"R Wang","year":"2021","unstructured":"Wang R, Gao Y, Liu A, Zhai G. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances. J Drug Target. 2021;29(7):687\u2013702. https:\/\/doi.org\/10.1080\/1061186X.2021.1878366.","journal-title":"J Drug Target"},{"key":"1772_CR99","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-47691-9","volume-title":"Ocular Drug Delivery: Advances, Challenges and Applications","author":"RT Addo","year":"2016","unstructured":"Addo RT. Ocular drug delivery: advances, challenges and Applications. Springer Cham; 2016."},{"key":"1772_CR100","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/164_2016_84","volume":"242","author":"B Yavuz","year":"2017","unstructured":"Yavuz B, Kompella UB. Ocular drug delivery. Handb Exp Pharmacol. 2017;242:57\u201393. https:\/\/doi.org\/10.1007\/164_2016_84.","journal-title":"Handb Exp Pharmacol"},{"issue":"8","key":"1772_CR101","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.drudis.2019.03.023","volume":"24","author":"Y Agban","year":"2019","unstructured":"Agban Y, Thakur SS, Mugisho OO, Rupenthal ID. Depot formulations to sustain periocular drug delivery to the posterior eye segment. Drug Discov Today. 2019;24(8):1458\u201369. https:\/\/doi.org\/10.1016\/j.drudis.2019.03.023.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1772_CR102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","volume":"148","author":"VP Ranta","year":"2010","unstructured":"Ranta VP, Mannermaa E, Lummepuro K, Subrizi A, Laukkanen A, Antopolsky M, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 2010;148(1):42\u20138. https:\/\/doi.org\/10.1016\/j.jconrel.2010.08.028.","journal-title":"J Control Release"},{"issue":"2","key":"1772_CR103","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/bioengineering11020179","volume":"11","author":"M Whalen","year":"2024","unstructured":"Whalen M, Akula M, McNamee SM, DeAngelis MM, Haider NB. Seeing the future: a review of ocular therapy. Bioeng (Basel). 2024;11(2):179. https:\/\/doi.org\/10.3390\/bioengineering11020179.","journal-title":"Bioeng (Basel)"},{"issue":"9","key":"1772_CR104","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/ph16091241","volume":"16","author":"KY Wu","year":"2023","unstructured":"Wu KY, Fujioka JK, Gholamian T, Zaharia M, Tran SD. Suprachoroidal injection: a Novel Approach for targeted drug delivery. Pharmaceuticals (Basel). 2023;16(9):1241. https:\/\/doi.org\/10.3390\/ph16091241.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"1772_CR105","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.3390\/jcm11164717","volume":"11","author":"C Irigoyen","year":"2022","unstructured":"Irigoyen C, Amenabar Alonso A, Sanchez-Molina J, Rodriguez-Hidalgo M, Lara-Lopez A, Ruiz-Ederra J. Subretinal Injection techniques for Retinal Disease: a review. J Clin Med. 2022;11(16):4717. https:\/\/doi.org\/10.3390\/jcm11164717.","journal-title":"J Clin Med"},{"issue":"13","key":"1772_CR106","doi-asserted-by":"publisher","first-page":"10535","DOI":"10.3390\/ijms241310535","volume":"24","author":"D Tripepi","year":"2023","unstructured":"Tripepi D, Jalil A, Ally N, Buzzi M, Moussa G, Rothschild PR, et al. The role of Subretinal Injection in Ophthalmic surgery: Therapeutic Agent Delivery and other indications. Int J Mol Sci. 2023;24(13):10535. https:\/\/doi.org\/10.3390\/ijms241310535.","journal-title":"Int J Mol Sci"},{"key":"1772_CR107","doi-asserted-by":"publisher","first-page":"101243","DOI":"10.1016\/j.preteyeres.2024.101243","volume":"99","author":"D Hristodorov","year":"2024","unstructured":"Hristodorov D, Lohoff T, Luneborg N, Mulder GJ, Clark SJ. Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment. Prog Retin Eye Res. 2024;99:101243. https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101243.","journal-title":"Prog Retin Eye Res"},{"key":"1772_CR108","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jconrel.2024.01.063","volume":"367","author":"MB Appell","year":"2024","unstructured":"Appell MB, Pejavar J, Pasupathy A, Rompicharla SVK, Abbasi S, Malmberg K, et al. Next generation therapeutics for retinal neurodegenerative diseases. J Control Release. 2024;367:708\u201336. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.063.","journal-title":"J Control Release"},{"key":"1772_CR109","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.preteyeres.2020.100862","volume":"80","author":"GB Melo","year":"2021","unstructured":"Melo GB, Cruz N, Emerson GG, Rezende FA, Meyer CH, Uchiyama S, et al. Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections. Prog Retin Eye Res. 2021;80:100862. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100862.","journal-title":"Prog Retin Eye Res"},{"key":"1772_CR110","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jconrel.2020.07.031","volume":"326","author":"BC Ilochonwu","year":"2020","unstructured":"Ilochonwu BC, Urtti A, Hennink WE, Vermonden T. Intravitreal hydrogels for sustained release of therapeutic proteins. J Control Release. 2020;326:419\u201341. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.031.","journal-title":"J Control Release"},{"issue":"14","key":"1772_CR111","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","volume":"57","author":"PM Hughes","year":"2005","unstructured":"Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57(14):2010\u201332. https:\/\/doi.org\/10.1016\/j.addr.2005.09.004.","journal-title":"Adv Drug Deliv Rev"},{"key":"1772_CR112","doi-asserted-by":"publisher","first-page":"114965","DOI":"10.1016\/j.addr.2023.114965","volume":"199","author":"S Zeng","year":"2023","unstructured":"Zeng S, Chen Y, Zhou F, Zhang T, Fan X, Chrzanowski W, et al. Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases. Adv Drug Deliv Rev. 2023;199:114965. https:\/\/doi.org\/10.1016\/j.addr.2023.114965.","journal-title":"Adv Drug Deliv Rev"},{"issue":"15","key":"1772_CR113","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1039\/d4nr00611a","volume":"16","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Cai S, Wu H, Pan J, Su M, Wei X, et al. Revolutionizing eye care: the game-changing applications of nano-antioxidants in ophthalmology. Nanoscale. 2024;16(15):7307\u201322. https:\/\/doi.org\/10.1039\/d4nr00611a.","journal-title":"Nanoscale"},{"key":"1772_CR114","unstructured":"(FDA) FaDA. Approved drug products with therapeutic equivalence evaluations (Orange Book). https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book#Publications (2024). Accessed 26\/08\/2024 2024."},{"issue":"8","key":"1772_CR115","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1021\/acs.biomac.3c00276","volume":"24","author":"T Silvestri","year":"2023","unstructured":"Silvestri T, Daruich A, De Palma FDE, Mollo V, Naud MC, Aleo D, et al. In Vitro and in vivo safety of Hyaluronic Acid-decorated microparticles for Intravitreal Injection of Palmitoylethanolamide, Citicoline, or glial-cell-derived neurotrophic factor. Biomacromolecules. 2023;24(8):3510\u201321. https:\/\/doi.org\/10.1021\/acs.biomac.3c00276.","journal-title":"Biomacromolecules"},{"issue":"1","key":"1772_CR116","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","volume":"11","author":"H Tsujinaka","year":"2020","unstructured":"Tsujinaka H, Fu J, Shen J, Yu Y, Hafiz Z, Kays J, et al. Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. Nat Commun. 2020;11(1):694. https:\/\/doi.org\/10.1038\/s41467-020-14340-x.","journal-title":"Nat Commun"},{"issue":"2","key":"1772_CR117","doi-asserted-by":"publisher","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","volume":"9","author":"M Herrera-Barrera","year":"2023","unstructured":"Herrera-Barrera M, Ryals RC, Gautam M, Jozic A, Landry M, Korzun T, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv. 2023;9(2):eadd4623. https:\/\/doi.org\/10.1126\/sciadv.add4623.","journal-title":"Sci Adv"},{"key":"1772_CR118","doi-asserted-by":"publisher","first-page":"121725","DOI":"10.1016\/j.ijpharm.2022.121725","volume":"620","author":"S Tavakoli","year":"2022","unstructured":"Tavakoli S, Puranen J, Bahrpeyma S, Lautala VE, Karumo S, Lajunen T, et al. Liposomal sunitinib for ocular drug delivery: a potential treatment for choroidal neovascularization. Int J Pharm. 2022;620:121725. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121725.","journal-title":"Int J Pharm"},{"key":"1772_CR119","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.actbio.2021.07.053","volume":"134","author":"G Tan","year":"2021","unstructured":"Tan G, Liu D, Zhu R, Pan H, Li J, Pan W. A core-shell nanoplatform as a nonviral vector for targeted delivery of genes to the retina. Acta Biomater. 2021;134:605\u201320. https:\/\/doi.org\/10.1016\/j.actbio.2021.07.053.","journal-title":"Acta Biomater"},{"key":"1772_CR120","doi-asserted-by":"publisher","first-page":"120188","DOI":"10.1016\/j.biomaterials.2020.120188","volume":"255","author":"S You","year":"2020","unstructured":"You S, Kim H, Jung HY, Kim B, Lee EJ, Kim JW, et al. Tuning surface functionalities of sub-10 nm-sized nanocarriers to target outer retina in designing drug delivery agents for intravitreal administration. Biomaterials. 2020;255:120188. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120188.","journal-title":"Biomaterials"},{"issue":"2","key":"1772_CR121","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.apsb.2023.09.001","volume":"14","author":"S Guo","year":"2024","unstructured":"Guo S, Li C, Wang C, Cao X, Liu X, Liang XJ, et al. pH-Responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy. Acta Pharm Sin B. 2024;14(2):781\u201394. https:\/\/doi.org\/10.1016\/j.apsb.2023.09.001.","journal-title":"Acta Pharm Sin B"},{"issue":"Pt 2","key":"1772_CR122","doi-asserted-by":"publisher","first-page":"130726","DOI":"10.1016\/j.ijbiomac.2024.130726","volume":"265","author":"M Dabkowska","year":"2024","unstructured":"Dabkowska M, Stukan I, Kosiorowska A, Szatanik A, Luczkowska K, Machalinska A, et al. In vitro and in vivo characterization of human serum albumin-based PEGylated nanoparticles for BDNF and NT3 codelivery. Int J Biol Macromol. 2024;265(Pt 2):130726. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.130726.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"1772_CR123","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1021\/acsnano.1c00680","volume":"15","author":"M Li","year":"2021","unstructured":"Li M, Xu Z, Zhang L, Cui M, Zhu M, Guo Y, et al. Targeted noninvasive treatment of Choroidal Neovascularization by Hybrid cell-membrane-cloaked biomimetic nanoparticles. ACS Nano. 2021;15(6):9808\u201319. https:\/\/doi.org\/10.1021\/acsnano.1c00680.","journal-title":"ACS Nano"},{"issue":"7","key":"1772_CR124","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/gels9070523","volume":"9","author":"NH Thang","year":"2023","unstructured":"Thang NH, Chien TB, Cuong DX. Polymer-based Hydrogels Applied in Drug Delivery: an overview. Gels. 2023;9(7):523. https:\/\/doi.org\/10.3390\/gels9070523.","journal-title":"Gels"},{"issue":"5","key":"1772_CR125","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1021\/acsami.2c17626","volume":"15","author":"N Duan","year":"2023","unstructured":"Duan N, Mei L, Hu L, Yin X, Wei X, Li Y, et al. Biomimetic, Injectable, and Self-Healing hydrogels with sustained release of Ranibizumab to treat retinal neovascularization. ACS Appl Mater Interfaces. 2023;15(5):6371\u201384. https:\/\/doi.org\/10.1021\/acsami.2c17626.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"1772_CR126","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1039\/D3MA01028G","volume":"5","author":"W Fan","year":"2024","unstructured":"Fan W, Chen M, Raza F, Zafar H, Jahan F, Chen Y, et al. pH-sensitive peptide hydrogel encapsulating the anti-angiogenesis drug conbercept and chemotherapeutic drug dox as a combination therapy for retinoblastoma. Mater Adv. 2024;5(5):2175\u201384. https:\/\/doi.org\/10.1039\/D3MA01028G.","journal-title":"Mater Adv"},{"key":"1772_CR127","doi-asserted-by":"publisher","first-page":"107159","DOI":"10.1016\/j.phrs.2024.107159","volume":"203","author":"J Wang","year":"2024","unstructured":"Wang J, Fan W, Liu B, Pu N, Wu H, Xue R, et al. Encapsulated cell technology: delivering cytokines to treat posterior ocular diseases. Pharmacol Res. 2024;203:107159. https:\/\/doi.org\/10.1016\/j.phrs.2024.107159.","journal-title":"Pharmacol Res"},{"key":"1772_CR128","doi-asserted-by":"publisher","first-page":"121948","DOI":"10.1016\/j.biomaterials.2022.121948","volume":"293","author":"FSY Wong","year":"2023","unstructured":"Wong FSY, Tsang KK, Chan BP, Lo ACY. Both non-coated and polyelectrolytically-coated intraocular collagen-alginate composite gels enhanced photoreceptor survival in retinal degeneration. Biomaterials. 2023;293:121948. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121948.","journal-title":"Biomaterials"},{"key":"1772_CR129","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2018.10.002","volume":"68","author":"G Orive","year":"2019","unstructured":"Orive G, Santos-Vizcaino E, Pedraz JL, Hernandez RM, Vela Ramirez JE, Dolatshahi-Pirouz A, et al. 3D cell-laden polymers to release bioactive products in the eye. Prog Retin Eye Res. 2019;68:67\u201382. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.10.002.","journal-title":"Prog Retin Eye Res"},{"issue":"7006","key":"1772_CR130","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature02873","volume":"431","author":"G Meister","year":"2004","unstructured":"Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343\u20139. https:\/\/doi.org\/10.1038\/nature02873.","journal-title":"Nature"},{"issue":"4","key":"1772_CR131","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1105\/tpc.2.4.279","volume":"2","author":"C Napoli","year":"1990","unstructured":"Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into Petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 1990;2(4):279\u201389. https:\/\/doi.org\/10.1105\/tpc.2.4.279.","journal-title":"Plant Cell"},{"issue":"3","key":"1772_CR132","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.mrrev.2011.09.001","volume":"728","author":"I Sifuentes-Romero","year":"2011","unstructured":"Sifuentes-Romero I, Milton SL, Garcia-Gasca A. Post-transcriptional gene silencing by RNA interference in non-mammalian vertebrate systems: where do we stand? Mutat Res. 2011;728(3):158\u201371. https:\/\/doi.org\/10.1016\/j.mrrev.2011.09.001.","journal-title":"Mutat Res"},{"issue":"6669","key":"1772_CR133","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806\u201311. https:\/\/doi.org\/10.1038\/35888.","journal-title":"Nature"},{"issue":"5","key":"1772_CR134","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaad.2008.08.017","volume":"59","author":"BK Sun","year":"2008","unstructured":"Sun BK, Tsao H. Small RNAs in development and disease. J Am Acad Dermatol. 2008;59(5):725\u201337. https:\/\/doi.org\/10.1016\/j.jaad.2008.08.017. quiz 38\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1772_CR135","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2796.2009.02189.x","volume":"267","author":"A Schroeder","year":"2010","unstructured":"Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med. 2010;267(1):9\u201321. https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02189.x.","journal-title":"J Intern Med"},{"key":"1772_CR136","doi-asserted-by":"publisher","first-page":"714","DOI":"10.17179\/excli2015-297","volume":"14","author":"T Martinez","year":"2015","unstructured":"Martinez T, Jimenez AI, Paneda C. Short-interference RNAs: becoming medicines. EXCLI J. 2015;14:714\u201346. https:\/\/doi.org\/10.17179\/excli2015-297.","journal-title":"EXCLI J"},{"issue":"12","key":"1772_CR137","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nchembio839","volume":"2","author":"D Bumcrot","year":"2006","unstructured":"Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711\u20139. https:\/\/doi.org\/10.1038\/nchembio839.","journal-title":"Nat Chem Biol"},{"key":"1772_CR138","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-biophys-083012-130404","volume":"42","author":"RC Wilson","year":"2013","unstructured":"Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys. 2013;42:217\u201339. https:\/\/doi.org\/10.1146\/annurev-biophys-083012-130404.","journal-title":"Annu Rev Biophys"},{"key":"1772_CR139","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fphys.2015.00119","volume":"6","author":"VS Kola","year":"2015","unstructured":"Kola VS, Renuka P, Madhav MS, Mangrauthia SK. Key enzymes and proteins of crop insects as candidate for RNAi based gene silencing. Front Physiol. 2015;6:119. https:\/\/doi.org\/10.3389\/fphys.2015.00119.","journal-title":"Front Physiol"},{"issue":"6","key":"1772_CR140","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrd2310","volume":"6","author":"A de Fougerolles","year":"2007","unstructured":"de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6):443\u201353. https:\/\/doi.org\/10.1038\/nrd2310.","journal-title":"Nat Rev Drug Discov"},{"issue":"6836","key":"1772_CR141","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494\u20138. https:\/\/doi.org\/10.1038\/35078107.","journal-title":"Nature"},{"issue":"2","key":"1772_CR142","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129\u201338. https:\/\/doi.org\/10.1038\/nrd2742.","journal-title":"Nat Rev Drug Discov"},{"key":"1772_CR143","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/B978-0-444-64046-8.00282-2","volume-title":"Comprehensive Biotechnology (Third Edition)","author":"W Xu","year":"2019","unstructured":"Xu W, Jiang X, Huang L. 5.42 - RNA interference technology. In: Moo-Young M, editor. Comprehensive Biotechnology (Third Edition). Oxford: Pergamon; 2019. pp. 560\u201375."},{"issue":"11\u201312","key":"1772_CR144","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.cr.7290371","volume":"15","author":"ML Yeung","year":"2005","unstructured":"Yeung ML, Bennasser Y, Le SY, Jeang KT, siRNA. miRNA and HIV: promises and challenges. Cell Res. 2005;15(11\u201312):935\u201346. https:\/\/doi.org\/10.1038\/sj.cr.7290371.","journal-title":"Cell Res"},{"issue":"11","key":"1772_CR145","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/chem.201003144","volume":"17","author":"MD Krebs","year":"2011","unstructured":"Krebs MD, Alsberg E. Localized, targeted, and sustained siRNA delivery. Chemistry. 2011;17(11):3054\u201362. https:\/\/doi.org\/10.1002\/chem.201003144.","journal-title":"Chemistry"},{"key":"1772_CR146","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-4614-4744-3_8","volume-title":"RNA interference from Biology to therapeutics","author":"F Pittella","year":"2013","unstructured":"Pittella F, Kataoka K. Polymeric micelles for siRNA delivery. In: Howard KA, editor. RNA interference from Biology to therapeutics. Boston, MA: Springer US; 2013. pp. 161\u201384."},{"issue":"3","key":"1772_CR147","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt936","volume":"22","author":"A Reynolds","year":"2004","unstructured":"Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22(3):326\u201330. https:\/\/doi.org\/10.1038\/nbt936.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1772_CR148","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/nar\/gkh247","volume":"32","author":"K Ui-Tei","year":"2004","unstructured":"Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004;32(3):936\u201348. https:\/\/doi.org\/10.1093\/nar\/gkh247.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1772_CR149","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bbrc.2004.02.157","volume":"316","author":"M Amarzguioui","year":"2004","unstructured":"Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun. 2004;316(4):1050\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2004.02.157.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1772_CR150","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.gene.2013.12.019","volume":"538","author":"Y Deng","year":"2014","unstructured":"Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014;538(2):217\u201327. https:\/\/doi.org\/10.1016\/j.gene.2013.12.019.","journal-title":"Gene"},{"key":"1772_CR151","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.omtn.2017.12.007","volume":"10","author":"L Zhang","year":"2018","unstructured":"Zhang L, Liang D, Chen C, Wang Y, Amu G, Yang J, et al. Circular siRNAs for reducing off-target effects and enhancing long-term gene silencing in cells and mice. Mol Ther Nucleic Acids. 2018;10:237\u201344. https:\/\/doi.org\/10.1016\/j.omtn.2017.12.007.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1772_CR152","doi-asserted-by":"publisher","first-page":"113834","DOI":"10.1016\/j.addr.2021.113834","volume":"178","author":"A Gupta","year":"2021","unstructured":"Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021;178:113834. https:\/\/doi.org\/10.1016\/j.addr.2021.113834.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"1772_CR153","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/mt.2011.294","volume":"20","author":"RL Kanasty","year":"2012","unstructured":"Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20(3):513\u201324. https:\/\/doi.org\/10.1038\/mt.2011.294.","journal-title":"Mol Ther"},{"issue":"7","key":"1772_CR154","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/mt.2009.91","volume":"17","author":"S Gao","year":"2009","unstructured":"Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009;17(7):1225\u201333. https:\/\/doi.org\/10.1038\/mt.2009.91.","journal-title":"Mol Ther"},{"issue":"1","key":"1772_CR155","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1754-1611-6-7","volume":"6","author":"A Thakur","year":"2012","unstructured":"Thakur A, Fitzpatrick S, Zaman A, Kugathasan K, Muirhead B, Hortelano G, et al. Strategies for ocular siRNA delivery: potential and limitations of non-viral nanocarriers. J Biol Eng. 2012;6(1):7. https:\/\/doi.org\/10.1186\/1754-1611-6-7.","journal-title":"J Biol Eng"},{"key":"1772_CR156","doi-asserted-by":"publisher","first-page":"1393646","DOI":"10.3389\/fmicb.2024.1393646","volume":"15","author":"H Motamedi","year":"2024","unstructured":"Motamedi H, Ari MM, Alvandi A, Abiri R. Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review. Front Microbiol. 2024;15:1393646. https:\/\/doi.org\/10.3389\/fmicb.2024.1393646.","journal-title":"Front Microbiol"},{"issue":"3","key":"1772_CR157","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/v15030698","volume":"15","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom K. Viral vectors in Gene Therapy: where do we stand in 2023? Viruses. 2023;15(3):698. https:\/\/doi.org\/10.3390\/v15030698.","journal-title":"Viruses"},{"key":"1772_CR158","doi-asserted-by":"publisher","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","volume":"905","author":"W Alshaer","year":"2021","unstructured":"Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174178.","journal-title":"Eur J Pharmacol"},{"key":"1772_CR159","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133\u201347. https:\/\/doi.org\/10.1016\/j.addr.2019.05.004.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1772_CR160","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A, Therapeutic, siRNA. State-of-the-art and future perspectives. BioDrugs. 2022;36(5):549\u201371. https:\/\/doi.org\/10.1007\/s40259-022-00549-3.","journal-title":"BioDrugs"},{"issue":"11","key":"1772_CR161","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00417-020-04797-3","volume":"258","author":"Z Wang","year":"2020","unstructured":"Wang Z, Liu A, Zhang H, Wang M, Tang Q, Huang Y, et al. Inhibition of retinal neovascularization by VEGF siRNA delivered via bioreducible lipid-like nanoparticles. Graefes Arch Clin Exp Ophthalmol. 2020;258(11):2407\u201318. https:\/\/doi.org\/10.1007\/s00417-020-04797-3.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1772_CR162","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.ejpb.2024.114296","volume":"199","author":"X Cao","year":"2024","unstructured":"Cao X, Su L, Chen H. A potent bioreducible ionizable lipid nanoparticle enables siRNA delivery for retinal neovascularization inhibition. Eur J Pharm Biopharm. 2024;199:114296. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114296.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"1772_CR163","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3390\/pharmaceutics15020611","volume":"15","author":"S Nishida","year":"2023","unstructured":"Nishida S, Takashima Y, Udagawa R, Ibaraki H, Seta Y, Ishihara H. A multifunctional hybrid nanocarrier for non-invasive siRNA delivery to the Retina. Pharmaceutics. 2023;15(2):611. https:\/\/doi.org\/10.3390\/pharmaceutics15020611.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1772_CR164","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bph.12330","volume":"170","author":"A Guzman-Aranguez","year":"2013","unstructured":"Guzman-Aranguez A, Loma P, Pintor J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol. 2013;170(4):730\u201347. https:\/\/doi.org\/10.1111\/bph.12330.","journal-title":"Br J Pharmacol"},{"key":"1772_CR165","unstructured":"ClinicalTrials.gov: https:\/\/clinicaltrials.gov\/search?cond=AMD&term=siRNA. (2024). Accessed 21\/08\/2024 2024."},{"issue":"9","key":"1772_CR166","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.ophtha.2012.03.043","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology. 2012;119(9):1867\u201373. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.043.","journal-title":"Ophthalmology"},{"issue":"1","key":"1772_CR167","doi-asserted-by":"publisher","first-page":"2272386","DOI":"10.1080\/13510002.2023.2272386","volume":"28","author":"J Gao","year":"2023","unstructured":"Gao J, Tao L, Jiang Z. Alleviate oxidative stress in diabetic retinopathy: antioxidant therapeutic strategies. Redox Rep. 2023;28(1):2272386. https:\/\/doi.org\/10.1080\/13510002.2023.2272386.","journal-title":"Redox Rep"},{"issue":"3","key":"1772_CR168","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","volume":"106","author":"TA Cabral de Guimaraes","year":"2022","unstructured":"Cabral de Guimaraes TA, Daich Varela M, Georgiou M, Michaelides M. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Ophthalmol. 2022;106(3):297\u2013304. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318452.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1772_CR169","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/medicina59071334","volume":"59","author":"D Rusciano","year":"2023","unstructured":"Rusciano D, Bagnoli P. Pharmacotherapy and Nutritional supplements for Neovascular Eye diseases. Med (Kaunas). 2023;59(7):1334. https:\/\/doi.org\/10.3390\/medicina59071334.","journal-title":"Med (Kaunas)"},{"issue":"3","key":"1772_CR170","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/medicina60030354","volume":"60","author":"C Russo","year":"2024","unstructured":"Russo C, Rusciano D, Santangelo R, Malaguarnera L. Options for topical treatment of oxidative Eye diseases with a special focus on Retinopathies. Med (Kaunas). 2024;60(3):354. https:\/\/doi.org\/10.3390\/medicina60030354.","journal-title":"Med (Kaunas)"},{"issue":"2","key":"1772_CR171","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/ajcn\/nqy114","volume":"108","author":"B Gopinath","year":"2018","unstructured":"Gopinath B, Liew G, Kifley A, Flood VM, Joachim N, Lewis JR, et al. Dietary flavonoids and the prevalence and 15-y incidence of age-related macular degeneration. Am J Clin Nutr. 2018;108(2):381\u20137. https:\/\/doi.org\/10.1093\/ajcn\/nqy114.","journal-title":"Am J Clin Nutr"},{"issue":"17","key":"1772_CR172","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1177\/1535370220926938","volume":"245","author":"T Parmar","year":"2020","unstructured":"Parmar T, Ortega JT, Jastrzebska B. Retinoid analogs and polyphenols as potential therapeutics for age-related macular degeneration. Exp Biol Med (Maywood). 2020;245(17):1615\u201325. https:\/\/doi.org\/10.1177\/1535370220926938.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"1772_CR173","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/antiox13050568","volume":"13","author":"D Basyal","year":"2024","unstructured":"Basyal D, Lee S, Kim HJ. Antioxidants and mechanistic insights for managing dry age-related Macular Degeneration. Antioxid (Basel). 2024;13(5):568. https:\/\/doi.org\/10.3390\/antiox13050568.","journal-title":"Antioxid (Basel)"},{"issue":"7","key":"1772_CR174","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/antiox10071125","volume":"10","author":"MY Hsu","year":"2021","unstructured":"Hsu MY, Hsiao YP, Lin YT, Chen C, Lee CM, Liao WC, et al. Quercetin alleviates the Accumulation of Superoxide in Sodium Iodate-Induced Retinal Autophagy by regulating mitochondrial reactive oxygen species homeostasis through enhanced Deacetyl-SOD2 via the Nrf2-PGC-1alpha-Sirt1 pathway. Antioxid (Basel). 2021;10(7):1125. https:\/\/doi.org\/10.3390\/antiox10071125.","journal-title":"Antioxid (Basel)"},{"issue":"3","key":"1772_CR175","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/ijms22031295","volume":"22","author":"D Delmas","year":"2021","unstructured":"Delmas D, Cornebise C, Courtaut F, Xiao J, Aires V. New highlights of Resveratrol: a review of Properties against Ocular diseases. Int J Mol Sci. 2021;22(3):1295. https:\/\/doi.org\/10.3390\/ijms22031295.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"1772_CR176","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.3390\/nu15153358","volume":"15","author":"J Blasiak","year":"2023","unstructured":"Blasiak J, Chojnacki J, Szczepanska J, Fila M, Chojnacki C, Kaarniranta K, et al. Epigallocatechin-3-Gallate, an active green tea component to support Anti-VEGFA therapy in Wet Age-Related Macular Degeneration. Nutrients. 2023;15(15):3358. https:\/\/doi.org\/10.3390\/nu15153358.","journal-title":"Nutrients"},{"key":"1772_CR177","doi-asserted-by":"publisher","first-page":"879901","DOI":"10.3389\/fmed.2022.879901","volume":"9","author":"M Peng","year":"2022","unstructured":"Peng M, Zhou X, Yao F, Li H, Song W, Xiong S, et al. (-)-Epicatechin provides Neuroprotection in Sodium Iodate-Induced Retinal Degeneration. Front Med (Lausanne). 2022;9:879901. https:\/\/doi.org\/10.3389\/fmed.2022.879901.","journal-title":"Front Med (Lausanne)"},{"key":"1772_CR178","doi-asserted-by":"publisher","first-page":"943321","DOI":"10.3389\/fimmu.2022.943321","volume":"13","author":"Z Cui","year":"2022","unstructured":"Cui Z, Zhao X, Amevor FK, Du X, Wang Y, Li D, et al. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Front Immunol. 2022;13:943321. https:\/\/doi.org\/10.3389\/fimmu.2022.943321.","journal-title":"Front Immunol"},{"issue":"12","key":"1772_CR179","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.3390\/ijms23126455","volume":"23","author":"WH Hu","year":"2022","unstructured":"Hu WH, Zhang XY, Leung KW, Duan R, Dong TT, Qin QW, et al. Resveratrol, an inhibitor binding to VEGF, restores the Pathology of abnormal angiogenesis in retinopathy of Prematurity (ROP) in mice: application by Intravitreal and Topical Instillation. Int J Mol Sci. 2022;23(12):6455. https:\/\/doi.org\/10.3390\/ijms23126455.","journal-title":"Int J Mol Sci"},{"key":"1772_CR180","doi-asserted-by":"publisher","first-page":"29546","DOI":"10.1038\/srep29546","volume":"6","author":"Y Yang","year":"2016","unstructured":"Yang Y, Qin YJ, Yip YW, Chan KP, Chu KO, Chu WK, et al. Green tea catechins are potent anti-oxidants that ameliorate sodium iodate-induced retinal degeneration in rats. Sci Rep. 2016;6:29546. https:\/\/doi.org\/10.1038\/srep29546.","journal-title":"Sci Rep"},{"key":"1772_CR181","doi-asserted-by":"publisher","first-page":"109639","DOI":"10.1016\/j.exer.2023.109639","volume":"235","author":"WC Gordon","year":"2023","unstructured":"Gordon WC, Kautzmann MI, Jun B, Cothern ML, Fang Z, Bazan NG. Rod-specific downregulation of omega-3 very-long-chain polyunsaturated fatty acid pathway in age-related macular degeneration. Exp Eye Res. 2023;235:109639. https:\/\/doi.org\/10.1016\/j.exer.2023.109639.","journal-title":"Exp Eye Res"},{"key":"1772_CR182","doi-asserted-by":"publisher","unstructured":"Merle B. Epid\u00e9miologie nutritionnelle et vieillissement oculaire: le cas de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA). Cahiers de Nutrition et de Di\u00e9t\u00e9tique. 2023;58(4):242\u2009\u2013\u200950. https:\/\/doi.org\/10.1016\/j.cnd.2023.04.001","DOI":"10.1016\/j.cnd.2023.04.001"},{"issue":"7","key":"1772_CR183","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaophthalmol.2022.1640","volume":"140","author":"EY Chew","year":"2022","unstructured":"Chew EY, Clemons TE, Agron E, Domalpally A, Keenan TDL, Vitale S, et al. Long-term Outcomes of Adding Lutein\/Zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related Macular Degeneration Progression: AREDS2 report 28. JAMA Ophthalmol. 2022;140(7):692\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.1640.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1772_CR184","doi-asserted-by":"publisher","first-page":"11016","DOI":"10.1038\/s41598-024-61833-6","volume":"14","author":"B Jiang","year":"2024","unstructured":"Jiang B, Wei X, Cai D, Wang X, Zhou X, Chen F, et al. Association between dietary consumption of fatty acids and age-related macular degeneration in the National Health and Nutrition Examination Survey. Sci Rep. 2024;14(1):11016. https:\/\/doi.org\/10.1038\/s41598-024-61833-6.","journal-title":"Sci Rep"},{"issue":"3","key":"1772_CR185","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ophtha.2020.08.018","volume":"128","author":"E Agron","year":"2021","unstructured":"Agron E, Mares J, Clemons TE, Swaroop A, Chew EY, Keenan TDL, et al. Dietary nutrient intake and progression to late age-related Macular Degeneration in the Age-Related Eye Disease studies 1 and 2. Ophthalmology. 2021;128(3):425\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.018.","journal-title":"Ophthalmology"},{"issue":"7","key":"1772_CR186","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.3390\/ijms25074099","volume":"25","author":"M Brito","year":"2024","unstructured":"Brito M, Sorbier C, Mignet N, Boudy V, Borchard G, Vacher G. Understanding the impact of Polyunsaturated fatty acids on age-related Macular Degeneration: a review. Int J Mol Sci. 2024;25(7):4099. https:\/\/doi.org\/10.3390\/ijms25074099.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1772_CR187","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3945\/jn.112.171033","volume":"143","author":"BM Merle","year":"2013","unstructured":"Merle BM, Delyfer MN, Korobelnik JF, Rougier MB, Malet F, Feart C, et al. High concentrations of plasma n3 fatty acids are associated with decreased risk for late age-related macular degeneration. J Nutr. 2013;143(4):505\u201311. https:\/\/doi.org\/10.3945\/jn.112.171033.","journal-title":"J Nutr"},{"key":"1772_CR188","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-030-27378-1_7","volume":"1185","author":"D Skowronska-Krawczyk","year":"2019","unstructured":"Skowronska-Krawczyk D, Chao DL. Long-chain polyunsaturated fatty acids and age-related Macular Degeneration. Adv Exp Med Biol. 2019;1185:39\u201343. https:\/\/doi.org\/10.1007\/978-3-030-27378-1_7.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"1772_CR189","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/archophthalmol.2009.76","volume":"127","author":"JS Tan","year":"2009","unstructured":"Tan JS, Wang JJ, Flood V, Mitchell P. Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue mountains Eye Study. Arch Ophthalmol. 2009;127(5):656\u201365. https:\/\/doi.org\/10.1001\/archophthalmol.2009.76.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"1772_CR190","doi-asserted-by":"publisher","first-page":"e13579","DOI":"10.1111\/acel.13579","volume":"21","author":"Y Liu","year":"2022","unstructured":"Liu Y, Bell BA, Song Y, Zhang K, Anderson B, Axelsen PH, et al. Deuterated docosahexaenoic acid protects against oxidative stress and geographic atrophy-like retinal degeneration in a mouse model with iron overload. Aging Cell. 2022;21(4):e13579. https:\/\/doi.org\/10.1111\/acel.13579.","journal-title":"Aging Cell"},{"issue":"1","key":"1772_CR191","doi-asserted-by":"publisher","first-page":"e000326","DOI":"10.1136\/bmjophth-2019-000326","volume":"4","author":"E Prokopiou","year":"2019","unstructured":"Prokopiou E, Kolovos P, Georgiou C, Kalogerou M, Potamiti L, Sokratous K, et al. Omega-3 fatty acids supplementation protects the retina from age-associated degeneration in aged C57BL\/6J mice. BMJ Open Ophthalmol. 2019;4(1):e000326. https:\/\/doi.org\/10.1136\/bmjophth-2019-000326.","journal-title":"BMJ Open Ophthalmol"},{"issue":"12","key":"1772_CR192","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.3390\/biomedicines10123222","volume":"10","author":"X Du","year":"2022","unstructured":"Du X, Byrne EM, Chen M, Xu H. Minocycline inhibits microglial activation and improves visual function in a chronic model of age-related retinal degeneration. Biomedicines. 2022;10(12):3222. https:\/\/doi.org\/10.3390\/biomedicines10123222.","journal-title":"Biomedicines"},{"key":"1772_CR193","doi-asserted-by":"publisher","first-page":"108953","DOI":"10.1016\/j.exer.2022.108953","volume":"217","author":"E Ozaki","year":"2022","unstructured":"Ozaki E, Delaney C, Campbell M, Doyle SL. Minocycline suppresses disease-associated microglia (DAM) in a model of photoreceptor cell degeneration. Exp Eye Res. 2022;217:108953. https:\/\/doi.org\/10.1016\/j.exer.2022.108953.","journal-title":"Exp Eye Res"},{"issue":"4","key":"1772_CR194","doi-asserted-by":"publisher","first-page":"e0239108","DOI":"10.1371\/journal.pone.0239108","volume":"16","author":"R Terauchi","year":"2021","unstructured":"Terauchi R, Kohno H, Watanabe S, Saito S, Watanabe A, Nakano T. Minocycline decreases CCR2-positive monocytes in the retina and ameliorates photoreceptor degeneration in a mouse model of retinitis pigmentosa. PLoS ONE. 2021;16(4):e0239108. https:\/\/doi.org\/10.1371\/journal.pone.0239108.","journal-title":"PLoS ONE"},{"issue":"1","key":"1772_CR195","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/jamaophthalmol.2023.5478","volume":"142","author":"S Aggarwal","year":"2024","unstructured":"Aggarwal S, Moir J, Hyman MJ, Kaufmann GT, Flores A, Hariprasad SM, et al. Metformin Use and Age-Related Macular Degeneration in patients without diabetes. JAMA Ophthalmol. 2024;142(1):53\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.5478.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"1772_CR196","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00417-023-06321-9","volume":"262","author":"Q Feng","year":"2024","unstructured":"Feng Q, Ruan X, Lu M, Bu S, Zhang Y. Metformin protects retinal pigment epithelium cells against H2O2-induced oxidative stress and inflammation via the Nrf2 signaling cascade. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2024;262(5):1519\u201330. https:\/\/doi.org\/10.1007\/s00417-023-06321-9.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"key":"1772_CR197","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.freeradbiomed.2024.03.024","volume":"219","author":"HH Dieguez","year":"2024","unstructured":"Dieguez HH, Romeo HE, Alaimo A, Bernal Aguirre NA, Calanni JS, Adan Arean JS, et al. Mitochondrial quality control in non-exudative age-related macular degeneration: from molecular mechanisms to structural and functional recovery. Free Radic Biol Med. 2024;219:17\u201330. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.03.024.","journal-title":"Free Radic Biol Med"},{"key":"1772_CR198","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c05447","author":"A Badia","year":"2023","unstructured":"Badia A, Duarri A, Salas A, Rosell J, Ramis J, Gusta MF, et al. Repeated Topical Administration of 3 nm Cerium Oxide nanoparticles reverts Disease Atrophic phenotype and arrests neovascular degeneration in AMD Mouse models. ACS Nano. 2023. https:\/\/doi.org\/10.1021\/acsnano.2c05447.","journal-title":"ACS Nano"},{"issue":"3","key":"1772_CR199","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/ICU.0000000000001043","volume":"35","author":"ST Berkowitz","year":"2024","unstructured":"Berkowitz ST, Finn AP. Gene therapy for age-related macular degeneration: potential, feasibility, and pitfalls. Curr Opin Ophthalmol. 2024;35(3):170\u20137. https:\/\/doi.org\/10.1097\/ICU.0000000000001043.","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"1772_CR200","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-Related Eye Disease Study Research G","year":"2001","unstructured":"Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report 8. Arch Ophthalmol. 2001;119(10):1417\u201336. https:\/\/doi.org\/10.1001\/archopht.119.10.1417.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1772_CR201","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamaophthalmol.2013.7376","volume":"132","author":"G Research","year":"2014","unstructured":"Age-Related Eye Disease Study 2, Research G, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3, et al. Secondary analyses of the effects of lutein\/zeaxanthin on age-related macular degeneration progression: AREDS2 report 3. JAMA Ophthalmol. 2014;132(2):142\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.7376.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"1772_CR202","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1167\/iovs.10-5637","volume":"51","author":"WT Wong","year":"2010","unstructured":"Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010;51(12):6131\u20139. https:\/\/doi.org\/10.1167\/iovs.10-5637.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1772_CR203","doi-asserted-by":"publisher","first-page":"8627","DOI":"10.1038\/srep08627","volume":"5","author":"N Vakalis","year":"2015","unstructured":"Vakalis N, Echiadis G, Pervena A, Deligiannis I, Kavalarakis E, Giannikakis S, et al. Intravitreal combination of dexamethasone sodium phosphate and bevacizumab in the treatment of exudative AMD. Sci Rep. 2015;5:8627. https:\/\/doi.org\/10.1038\/srep08627.","journal-title":"Sci Rep"},{"key":"1772_CR204","doi-asserted-by":"publisher","first-page":"122081","DOI":"10.1016\/j.ijpharm.2022.122081","volume":"625","author":"H Shi","year":"2022","unstructured":"Shi H, Zhu Y, Xing C, Li S, Bao Z, Lei L, et al. An injectable thermosensitive hydrogel for dual delivery of diclofenac and avastin(R) to effectively suppress inflammatory corneal neovascularization. Int J Pharm. 2022;625:122081. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122081.","journal-title":"Int J Pharm"},{"issue":"5","key":"1772_CR205","doi-asserted-by":"publisher","first-page":"e2302192","DOI":"10.1002\/adhm.202302192","volume":"13","author":"H Zhu","year":"2024","unstructured":"Zhu H, Ye J, Wu Y, Cheng Y, Su M, Dai Q, et al. A synergistic therapy with antioxidant and Anti-VEGF: toward its safe and effective elimination for corneal neovascularization. Adv Healthc Mater. 2024;13(5):e2302192. https:\/\/doi.org\/10.1002\/adhm.202302192.","journal-title":"Adv Healthc Mater"},{"issue":"23","key":"1772_CR206","doi-asserted-by":"publisher","first-page":"e2314095","DOI":"10.1002\/adma.202314095","volume":"36","author":"J Shen","year":"2024","unstructured":"Shen J, Chen L, Lv X, Liu N, Miao Y, Zhang Q, et al. Emerging Co-assembled and Sustained Released Natural Medicinal nanoparticles for Multitarget Therapy of Choroidal Neovascularization. Adv Mater. 2024;36(23):e2314095. https:\/\/doi.org\/10.1002\/adma.202314095.","journal-title":"Adv Mater"},{"key":"1772_CR207","doi-asserted-by":"publisher","first-page":"101156","DOI":"10.1016\/j.apmt.2021.101156","volume":"24","author":"L-J Luo","year":"2021","unstructured":"Luo L-J, Jian H-J, Harroun SG, Lai J-Y, Unnikrishnan B, Huang C-C. Targeting nanocomposites with anti-oxidative\/inflammatory\/angiogenic activities for synergistically alleviating macular degeneration. Appl Mater Today. 2021;24:101156. https:\/\/doi.org\/10.1016\/j.apmt.2021.101156.","journal-title":"Appl Mater Today"},{"key":"1772_CR208","doi-asserted-by":"publisher","first-page":"122809","DOI":"10.1016\/j.ijpharm.2023.122809","volume":"636","author":"MCA Guerra","year":"2023","unstructured":"Guerra MCA, Neto JT, Gomes MG, Dourado LFN, Orefice RL, Heneine LGD, et al. Nanofiber-coated implants: development and safety after intravitreal application in rabbits. Int J Pharm. 2023;636:122809. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122809.","journal-title":"Int J Pharm"},{"issue":"1","key":"1772_CR209","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-023-01829-y","volume":"21","author":"W Su","year":"2023","unstructured":"Su W, Liu C, Jiang X, Lv Y, Chen Q, Shi J, et al. An intravitreal-injectable hydrogel depot doped borneol-decorated dual-drug-coloaded microemulsions for long-lasting retina delivery and synergistic therapy of wAMD. J Nanobiotechnol. 2023;21(1):71. https:\/\/doi.org\/10.1186\/s12951-023-01829-y.","journal-title":"J Nanobiotechnol"},{"issue":"14","key":"1772_CR210","doi-asserted-by":"publisher","first-page":"e2303659","DOI":"10.1002\/adhm.202303659","volume":"13","author":"C Liu","year":"2024","unstructured":"Liu C, Su W, Jiang X, Lv Y, Kong F, Chen Q, et al. A sustainable retinal drug Co-delivery for boosting therapeutic efficacy in wAMD: unveiling multifaceted evidence and synergistic mechanisms. Adv Healthc Mater. 2024;13(14):e2303659. https:\/\/doi.org\/10.1002\/adhm.202303659.","journal-title":"Adv Healthc Mater"},{"key":"1772_CR211","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.12659\/msm.895977","volume":"21","author":"D Wygledowska-Promienska","year":"2015","unstructured":"Wygledowska-Promienska D, Piotrowska-Gwozdz A, Piotrowska-Seweryn A, Mazur-Piotrowska G. Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: a Pilot Study Aflibercept and Bromfenac in AMD. Med Sci Monit. 2015;21:3906\u201312. https:\/\/doi.org\/10.12659\/msm.895977.","journal-title":"Med Sci Monit"},{"issue":"4","key":"1772_CR212","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamaophthalmol.2016.0045","volume":"134","author":"J Sridhar","year":"2016","unstructured":"Sridhar J, Hsu J, Shahlaee A, Garg SJ, Spirn MJ, Fineman MS, et al. Topical dorzolamide-timolol with Intravitreous Anti-vascular endothelial growth factor for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2016;134(4):437\u201343. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.0045.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"1772_CR213","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/IAE.0b013e3180323de7","volume":"27","author":"AJ Augustin","year":"2007","unstructured":"Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27(2):133\u201340. https:\/\/doi.org\/10.1097\/IAE.0b013e3180323de7.","journal-title":"Retina"},{"issue":"2","key":"1772_CR214","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canlet.2015.01.011","volume":"359","author":"D Dong","year":"2015","unstructured":"Dong D, Gao W, Liu Y, Qi XR. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. Cancer Lett. 2015;359(2):178\u201386. https:\/\/doi.org\/10.1016\/j.canlet.2015.01.011.","journal-title":"Cancer Lett"},{"issue":"7","key":"1772_CR215","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/pharmaceutics14071369","volume":"14","author":"M Jin","year":"2022","unstructured":"Jin M, Zeng B, Liu Y, Jin L, Hou Y, Liu C, et al. Co-delivery of Repurposing Itraconazole and VEGF siRNA by Composite Nanoparticulate System for collaborative anti-angiogenesis and Anti-tumor efficacy against breast Cancer. Pharmaceutics. 2022;14(7):1369. https:\/\/doi.org\/10.3390\/pharmaceutics14071369.","journal-title":"Pharmaceutics"},{"key":"1772_CR216","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.crphar.2022.100103","volume":"3","author":"K Kumar","year":"2022","unstructured":"Kumar K, Rani V, Mishra M, Chawla R. New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy. Curr Res Pharmacol Drug Discov. 2022;3:100103. https:\/\/doi.org\/10.1016\/j.crphar.2022.100103.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"20","key":"1772_CR217","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.7150\/thno.32416","volume":"9","author":"F Li","year":"2019","unstructured":"Li F, Wang Y, Chen WL, Wang DD, Zhou YJ, You BG, et al. Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation Effect via multi-functional nanoparticles for Orthotopic Non-small Cell Lung Cancer Treatment. Theranostics. 2019;9(20):5886\u201398. https:\/\/doi.org\/10.7150\/thno.32416.","journal-title":"Theranostics"},{"key":"1772_CR218","doi-asserted-by":"publisher","first-page":"102218","DOI":"10.1016\/j.nano.2020.102218","volume":"28","author":"L Wen","year":"2020","unstructured":"Wen L, Wen C, Zhang F, Wang K, Yuan H, Hu F. siRNA and chemotherapeutic molecules entrapped into a redox-responsive platform for targeted synergistic combination therapy of glioma. Nanomedicine. 2020;28:102218. https:\/\/doi.org\/10.1016\/j.nano.2020.102218.","journal-title":"Nanomedicine"},{"key":"1772_CR219","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejps.2017.10.036","volume":"111","author":"G Zheng","year":"2018","unstructured":"Zheng G, Zhao R, Xu A, Shen Z, Chen X, Shao J. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. Eur J Pharm Sci. 2018;111:492\u2013502. https:\/\/doi.org\/10.1016\/j.ejps.2017.10.036.","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"1772_CR220","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/nano10122466","volume":"10","author":"I Ponton","year":"2020","unstructured":"Ponton I, Marti Del Rio A, Gomez Gomez M, Sanchez-Garcia D. Preparation and applications of organo-silica hybrid mesoporous silica nanoparticles for the co-delivery of drugs and nucleic acids. Nanomaterials (Basel). 2020;10(12):2466. https:\/\/doi.org\/10.3390\/nano10122466.","journal-title":"Nanomaterials (Basel)"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01772-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01772-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01772-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T12:25:17Z","timestamp":1749039917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01772-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":220,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01772-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"16 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors agree to publish this article in Drug Delivery and Translational Research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}